## TABLE OF CONTENTS

### HIGHLIGHTS

**761** Selected Articles from This Issue

### SMALL MOLECULE THERAPEUTICS

**763** Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer


**787** The Monoacylglycerol Lipase Inhibitor JZL184 Inhibits Lung Cancer Cell Invasion and Metastasis via the CB1 Cannabinoid Receptor

Jan Lukas Prüser, Robert Ramer, Felix Wittig, Igor Ivanov, Jutta Merkord, and Burkhard Hinz

**803** Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis

Yuhua Wang, Ram Naresh Pandey, Kaushik Roychowdhury, David Milewski, Tanya V. Kalin, Sara Szabo, Joseph G. Pressey, and Rashmi S. Hegde

**816** Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma

Yongmei Feng, Gaurav Pathria, Susanne Heynen-Genel, Michael Jackson, Brian James, Jun Yin, David A. Scott, and Ze’ev A. Ronai

### LARGE MOLECULE THERAPEUTICS

**833** Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress

Korie A. Grayson, Jacob M. Hope, Wenjun Wang, Cynthia A. Reinhart-King, and Michael R. King

**846** Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells


**859** A Novel Antibody–IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis

Riccardo Corbellari, Marco Stringhini, Jaqueline Mock, Tiziano Ongaro, Alessandra Villa, Dario Neri, and Roberto De Luca

**872** Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response

Raanan Greenman, Yoav Pizem, Maya Haus-Cohen, Alona Goor, Guy Horev, Galit Denkberg, Keren Sinik, Yael Elbaz, Vered Bronner, Anat Glioberson Levin, Galit Horn, Shai Shen-Orr, and Yoram Reiter

See related article, p. 946

**885** Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Aleksandr V. Yurkovetskiy, Natalya D. Bodiyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Ut tard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovanesyan, Charlie Bu, Alex J. Johnson, Venu R. Gurijala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxin Zhang, Peter U. Park, Donald A. Bergstrom, and Timothy B. Lowinger
The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy, Mao Yin, Charlie Bu, Patrick R. Conlon, Damon R. Demady, Michael J. DeVit, Dmitry R. Gumerov, Venu R. Gurijala, Winnie Lee, Dennis McGillicuddy, Peter U. Park, Laura L. Poling, Marina Protopova, Liu Liang Qin, Cheri A. Stevenson, Elena Ter-Ovanesyan, Alex Uttard, Dongmei Xiao, Jian Xu, Ling Xu, Donald A. Bergstrom, and Timothy B. Lowinger

Interleukin-4 Receptor Inhibition Targeting Metastasis Independent of Macrophages

Megan M. Cleary, Narendra Bharathy, Jinu Abraham, Jin-Ah Kim, Erin R. Rudzinski, Joel E. Michalek, and Charles Keller

Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models


Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII

Alexander Sternjak, Fei Lee, Oliver Thomas, Mercedesz Balazs, Joachim Wahl, Grit Lorenczewski, Ines Ullrich, Markus Muenz, Benno Rattel, Julie M. Bailis, and Matthias Friedrich

PGE2 Released by Pancreatic Cancer Cells Undergoing ER Stress Transfers the Stress to DCs Impairing Their Immune Function

Maria Saveria Gilardini Montani, Rossella Benedetti, Silvia Piconese, Fabio Maria Pucinelli, Anna Maria Timperio, Maria Anela Romeo, Laura Masuelli, Maurizio Mattei, Roberto Bei, Gabriella D’Orazi, and Mara Cirone

Phenotypic Models of CAR T-Cell Activation Elucidate the Pivotal Regulatory Role of CAR Downmodulation

Raanan Greenman, Yoav Pizem, Maya Haus-Cohen, Guy Horev, Galit Denkberg, Shai Shen-Orr, Jacob Rubinstein, and Yoram Reiter

See related article, p. 872

In this month’s cover, Dwivedi and colleagues demonstrate the binding of a single chain variable fragment (scFv) of the humanized anti-CD19 CAR with CD19 target antigen, obtained through molecular modelling. The unique composition of amino acid residues of the framework region as well as the complementary determining regions (CDRs) of the scFv resulted into the scFv interaction to the CD19 antigen with high binding affinity and with high structural flexibility. Further preclinical and ex vivo studies confirmed that the distinct structural modification in CAR design confers the novel humanized anti-CD19 CAR with a favorable balance of efficacy to toxicity. Read the article on page 846.